Sederma claims world first with new anti-ageing active targeting microRNAs
MicroRNAs are a class of post-transcriptional regulators and recent evidence suggests that they are key regulators of gene expression and further understanding could lead to the development of anti-ageing actives.
Sederma has done this with its new Senestem product that targets the microRNAs to prevent the decline of protein synthesis that worsens with age and is associated with unsightly phenotypic changes.
Combat ageing
The company says that this micro approach leads to a visible macro embellishment: skin recovers its density, firmness and elasticity, age spots are lightened.
“Skin changes in many important ways with age,” says Sederma. “The skin becomes thinner, begins to sag, and loses its elasticity and smoothness. On the areas overexposed to UV, like the face and the hands, pigmented age spots appear.”
This led the Paris-headquartered firm to develop Senestem to fade signs of senescence (the process of deterioration with age) by a breakthrough approach targeting the microRNAs.
Tests
The active has been tested and results are visible after the first month of use of a cream containing Senestem: skin firmness and elasticity are respectively increased by 31 per cent and 22 per cent; thickness and density are restored with a calculated youth gain of 6 years.
“After 2 months the visible age correcting benefits are optimised: the pigmented age spots are notably lightened with a greater efficiency than on the normally pigmented skin,” claims Sederma. “The skin is smoothened and an overall youthful appearance is observed.”
This active ingredient is the culmination of Sederma’s expertise with IRB’s exclusive HTN technology - an industrial culture method to produce plant active ingredients at the highest level of safety and quality in eco-sustainable conditions.
